- Home
- ETO vs TRVI Comparison
ETO vs TRVI Comparison
Compare ETO & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETO
- TRVI
- Stock Information
- Founded
- ETO 2004
- TRVI 2011
- Country
- ETO United States
- TRVI United States
- Employees
- ETO N/A
- TRVI N/A
- Industry
- ETO Investment Managers
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- ETO Finance
- TRVI Health Care
- Exchange
- ETO Nasdaq
- TRVI Nasdaq
- Market Cap
- ETO 387.3M
- TRVI 383.4M
- IPO Year
- ETO N/A
- TRVI 2019
- Fundamental
- Price
- ETO $23.03
- TRVI $6.07
- Analyst Decision
- ETO
- TRVI Strong Buy
- Analyst Count
- ETO 0
- TRVI 8
- Target Price
- ETO N/A
- TRVI $17.56
- AVG Volume (30 Days)
- ETO 26.5K
- TRVI 1.5M
- Earning Date
- ETO 01-01-0001
- TRVI 05-06-2025
- Dividend Yield
- ETO 6.67%
- TRVI N/A
- EPS Growth
- ETO N/A
- TRVI N/A
- EPS
- ETO N/A
- TRVI N/A
- Revenue
- ETO N/A
- TRVI N/A
- Revenue This Year
- ETO N/A
- TRVI N/A
- Revenue Next Year
- ETO N/A
- TRVI N/A
- P/E Ratio
- ETO N/A
- TRVI N/A
- Revenue Growth
- ETO N/A
- TRVI N/A
- 52 Week Low
- ETO $19.85
- TRVI $2.30
- 52 Week High
- ETO $25.21
- TRVI $7.39
- Technical
- Relative Strength Index (RSI)
- ETO 43.17
- TRVI 54.43
- Support Level
- ETO $22.36
- TRVI $4.85
- Resistance Level
- ETO $23.69
- TRVI $6.39
- Average True Range (ATR)
- ETO 0.94
- TRVI 0.46
- MACD
- ETO 0.03
- TRVI -0.02
- Stochastic Oscillator
- ETO 61.19
- TRVI 78.71
About ETO Eaton Vance Tax-Advantage Global Dividend Opp
Eaton Vance Tax-advtgd Global Divid Oppo is a diversified, closed-end management investment company. Its investment objective is to provide a high level of after-tax total return consisting of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. The portfolio of investments consists of capital markets, chemicals, diversified, beverages, banks, electric utilities, oil, gas and consumable fuels, personal products, and other areas.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.